

# Linda M Liau

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4336378/publications.pdf>

Version: 2024-02-01

193  
papers

24,894  
citations

13865

67  
h-index

7348

152  
g-index

206  
all docs

206  
docs citations

206  
times ranked

30046  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. <i>Nature</i> , 2009, 462, 739-744.	27.8	3,315
2	Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors. <i>New England Journal of Medicine</i> , 2005, 353, 2012-2024.	27.0	1,376
3	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. <i>Nature Medicine</i> , 2019, 25, 477-486.	30.7	932
4	Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 20007-20012.	7.1	927
5	High-throughput oncogene mutation profiling in human cancer. <i>Nature Genetics</i> , 2007, 39, 347-351.	21.4	927
6	Intertumoral Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , 2017, 31, 737-754.e6.	16.8	836
7	The whole-genome landscape of medulloblastoma subtypes. <i>Nature</i> , 2017, 547, 311-317.	27.8	787
8	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. <i>Nature</i> , 2012, 488, 49-56.	27.8	761
9	Gene Expression Profiling of Gliomas Strongly Predicts Survival. <i>Cancer Research</i> , 2004, 64, 6503-6510.	0.9	659
10	Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma. <i>PLoS Medicine</i> , 2008, 5, e8.	8.4	499
11	Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment. <i>Clinical Cancer Research</i> , 2005, 11, 5515-5525.	7.0	498
12	Evidence for Sequenced Molecular Evolution of <i>IDH1</i> Mutant Glioblastoma From a Distinct Cell of Origin. <i>Journal of Clinical Oncology</i> , 2011, 29, 4482-4490.	1.6	420
13	Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme. <i>Journal of Clinical Oncology</i> , 2011, 29, 142-148.	1.6	418
14	Subgroup-Specific Prognostic Implications of <i>TP53</i> Mutation in Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2927-2935.	1.6	381
15	Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy. <i>Clinical Cancer Research</i> , 2011, 17, 1603-1615.	7.0	378
16	First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. <i>Journal of Translational Medicine</i> , 2018, 16, 142.	4.4	376
17	Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. <i>Nature</i> , 2010, 465, 966-966.	27.8	360
18	Somatic mutations of the Parkinson's disease-associated gene <i>PARK2</i> in glioblastoma and other human malignancies. <i>Nature Genetics</i> , 2010, 42, 77-82.	21.4	336

#	ARTICLE	IF	CITATIONS
19	Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. <i>Nature Genetics</i> , 2013, 45, 253-261.	21.4	324
20	Differential Sensitivity of Glioma- versus Lung Cancer- Specific EGFR Mutations to EGFR Kinase Inhibitors. <i>Cancer Discovery</i> , 2012, 2, 458-471.	9.4	304
21	Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain. <i>PLoS Medicine</i> , 2006, 3, e485.	8.4	298
22	BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e109.	5.1	284
23	Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. <i>Journal of Neuro-Oncology</i> , 2012, 107, 197-205.	2.9	280
24	Gene expression profiling identifies molecular subtypes of gliomas. <i>Oncogene</i> , 2003, 22, 4918-4923.	5.9	264
25	Cytogenetic Prognostication Within Medulloblastoma Subgroups. <i>Journal of Clinical Oncology</i> , 2014, 32, 886-896.	1.6	263
26	Identification of molecular subtypes of glioblastoma by gene expression profiling. <i>Oncogene</i> , 2003, 22, 2361-2373.	5.9	247
27	The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 9435-9440.	7.1	246
28	Treatment of intracranial gliomas with bone marrow- derived dendritic cells pulsed with tumor antigens. <i>Journal of Neurosurgery</i> , 1999, 90, 1115-1124.	1.6	224
29	Primary Glioblastomas Express Mesenchymal Stem-Like Properties. <i>Molecular Cancer Research</i> , 2006, 4, 607-619.	3.4	215
30	Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. <i>Nature Biotechnology</i> , 2009, 27, 77-83.	17.5	210
31	Neurosphere Formation Is an Independent Predictor of Clinical Outcome in Malignant Glioma. <i>Stem Cells</i> , 2009, 27, 980-987.	3.2	207
32	The TLR-7 Agonist, Imiquimod, Enhances Dendritic Cell Survival and Promotes Tumor Antigen-Specific T Cell Priming: Relation to Central Nervous System Antitumor Immunity. <i>Journal of Immunology</i> , 2006, 176, 157-164.	0.8	193
33	Distinct Transcription Profiles of Primary and Secondary Glioblastoma Subgroups. <i>Cancer Research</i> , 2006, 66, 159-167.	0.9	182
34	Phase II Pilot Study of Bevacizumab in Combination with Temozolomide and Regional Radiation Therapy for Up-Front Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Interim Analysis of Safety and Tolerability. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1372-1380.	0.8	169
35	Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients. <i>Neuro-Oncology</i> , 2017, 19, 1494-1502.	1.2	168
36	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 2468-2477.	1.6	160

#	ARTICLE	IF	CITATIONS
37	Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. <i>Science Translational Medicine</i> , 2016, 8, 341ra75.	12.4	158
38	An Essential Requirement for the SCAP/SREBP Signaling Axis to Protect Cancer Cells from Lipotoxicity. <i>Cancer Research</i> , 2013, 73, 2850-2862.	0.9	148
39	Relationship between Gene Expression and Enhancement in Glioblastoma Multiforme: Exploratory DNA Microarray Analysis. <i>Radiology</i> , 2008, 249, 268-277.	7.3	146
40	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 126, 917-929.	7.7	146
41	Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. <i>Journal of Neuroscience Research</i> , 2008, 86, 48-60.	2.9	144
42	Cytomegalovirus Immunity after Vaccination with Autologous Glioblastoma Lysate. <i>New England Journal of Medicine</i> , 2008, 359, 539-541.	27.0	135
43	Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. <i>Neuro-Oncology</i> , 2018, 20, 1383-1392.	1.2	135
44	Proteasomal and Genetic Inactivation of the NF1 Tumor Suppressor in Gliomagenesis. <i>Cancer Cell</i> , 2009, 16, 44-54.	16.8	132
45	Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. <i>Neuro-Oncology</i> , 2013, 15, 57-68.	1.2	128
46	PD-1 blockade enhances the vaccination-induced immune response in glioma. <i>JCI Insight</i> , 2016, 1, .	5.0	128
47	Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, now287.	1.2	128
48	Genomic Landscape of Meningiomas. <i>Brain Pathology</i> , 2010, 20, 751-762.	4.1	124
49	Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade III diffuse gliomas. <i>Journal of Neuro-Oncology</i> , 2017, 134, 177-188.	2.9	118
50	Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. <i>Journal of Neuro-Oncology</i> , 2009, 94, 1-19.	2.9	111
51	Comparison of Glioma-associated Antigen Peptide-loaded Versus Autologous Tumor Lysate-loaded Dendritic Cell Vaccination in Malignant Glioma Patients. <i>Journal of Immunotherapy</i> , 2013, 36, 152-157.	2.4	111
52	The TLR7 Agonist Imiquimod Enhances the Anti-Melanoma Effects of a Recombinant <i>Listeria monocytogenes</i> Vaccine. <i>Journal of Immunology</i> , 2005, 175, 1983-1990.	0.8	110
53	Relationship between Survival and Edema in Malignant Gliomas: Role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2. <i>Clinical Cancer Research</i> , 2007, 13, 2592-2598.	7.0	108
54	A Microfluidic Platform for Systems Pathology: Multiparameter Single-Cell Signaling Measurements of Clinical Brain Tumor Specimens. <i>Cancer Research</i> , 2010, 70, 6128-6138.	0.9	106

#	ARTICLE	IF	CITATIONS
55	The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6459-6464.	7.1	99
56	Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro-Oncology, 2013, 15, 370-381.	1.2	97
57	pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. Neuro-Oncology, 2015, 17, 1514-1524.	1.2	96
58	Altered functional connectivity of the default mode network in diffuse gliomas measured with pseudo-resting state fMRI. Journal of Neuro-Oncology, 2014, 116, 373-379.	2.9	95
59	Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nature Communications, 2021, 12, 6938.	12.8	93
60	NF1 mutation drives neuronal activity-dependent initiation of optic glioma. Nature, 2021, 594, 277-282.	27.8	91
61	Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone. Journal of Neuro-Oncology, 2010, 96, 359-367.	2.9	86
62	Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica, 2018, 136, 227-237.	7.7	86
63	Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM Patients. PLoS ONE, 2012, 7, e32614.	2.5	83
64	Large-scale assessment of the gliomasphere model system. Neuro-Oncology, 2016, 18, 1367-1378.	1.2	82
65	Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10220-10225.	7.1	79
66	Multiinstitutional validation of the University of California at San Francisco Low-Grade Glioma Prognostic Scoring System. Journal of Neurosurgery, 2009, 111, 203-210.	1.6	78
67	Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex bound immunogenic peptides induced by interferon- $\alpha$ and interferon- $\beta$ treatment of human glioblastoma multiforme. Journal of Neurosurgery, 2004, 100, 310-319.	1.6	74
68	Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma. Neuro-Oncology, 2012, 14, 333-343.	1.2	74
69	Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF- $\beta$ 2 antisense gene. Neurological Research, 1998, 20, 742-747.	1.3	73
70	p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. Oncogene, 2004, 23, 1283-1290.	5.9	67
71	Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy. Neuro-Oncology, 2017, 19, 189.	1.2	65
72	TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination. Cancer Immunology Research, 2016, 4, 412-418.	3.4	64

#	ARTICLE	IF	CITATIONS
73	NK and CD4 Cells Collaborate to Protect against Melanoma Tumor Formation in the Brain. <i>Journal of Immunology</i> , 2006, 177, 8448-8455.	0.8	59
74	Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1279-1289.	4.2	59
75	Unique challenges for glioblastoma immunotherapy—discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. <i>Neuro-Oncology</i> , 2021, 23, 356-375.	1.2	59
76	Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation. <i>Clinical Cancer Research</i> , 2019, 25, 1913-1922.	7.0	57
77	Identification of Retinol Binding Protein 1 Promoter Hypermethylation in Isocitrate Dehydrogenase 1 and 2 Mutant Gliomas. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1458-1469.	6.3	56
78	IDH Mutations in Human Glioma. <i>Neurosurgery Clinics of North America</i> , 2012, 23, 471-480.	1.7	53
79	Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients. <i>PLoS ONE</i> , 2015, 10, e0141334.	2.5	52
80	HLA Markers DQ8 and DR53 Are Associated With Lymphocytic Hypophysitis and May Aid in Differential Diagnosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4092-4097.	3.6	52
81	Management of low-grade glioma: a systematic review and meta-analysis. <i>Neuro-Oncology Practice</i> , 2019, 6, 249-258.	1.6	52
82	Simulation, phantom validation, and clinical evaluation of fast pH-weighted molecular imaging using amine chemical exchange saturation transfer echo planar imaging (CEST-EPI) in glioma at 3T. <i>NMR in Biomedicine</i> , 2016, 29, 1563-1576.	2.8	51
83	Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. <i>Neuro-Oncology</i> , 2014, 16, 815-822.	1.2	49
84	Bioluminescent Imaging of Melanoma in Live Mice. <i>Journal of Investigative Dermatology</i> , 2005, 125, 159-165.	0.7	48
85	Disruption of the PACAP gene promotes medulloblastoma in ptc1 mutant mice. <i>Developmental Biology</i> , 2008, 313, 359-370.	2.0	48
86	Protective Properties of Radio-Chemoresistant Glioblastoma Stem Cell Clones Are Associated with Metabolic Adaptation to Reduced Glucose Dependence. <i>PLoS ONE</i> , 2013, 8, e80397.	2.5	48
87	Contrast-enhancing tumor growth dynamics of preoperative, treatment-naïve human glioblastoma. <i>Cancer</i> , 2016, 122, 1718-1727.	4.1	47
88	The transcriptional landscape of Shh medulloblastoma. <i>Nature Communications</i> , 2021, 12, 1749.	12.8	47
89	Tumor immunity within the central nervous system stimulated by recombinant <i>Listeria monocytogenes</i> vaccination. <i>Cancer Research</i> , 2002, 62, 2287-93.	0.9	47
90	Knockdown of CypA inhibits interleukin-8 (IL-8) and IL-8-mediated proliferation and tumor growth of glioblastoma cells through down-regulated NF- $\kappa$ B. <i>Journal of Neuro-Oncology</i> , 2011, 101, 1-14.	2.9	46

#	ARTICLE	IF	CITATIONS
91	Characterization of a novel and potent 5-hydroxytryptamine1A receptor antagonist. <i>Pharmacology Biochemistry and Behavior</i> , 1991, 38, 555-559.	2.9	45
92	Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1195-1203.	0.8	45
93	Dendritic Cell Vaccines for Brain Tumors. <i>Neurosurgery Clinics of North America</i> , 2010, 21, 139-157.	1.7	44
94	The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells. , 2014, 2, 8.		42
95	Immunology and Immunotherapy in Neurosurgical Disease. <i>Neurosurgery</i> , 2003, 53, 144-153.	1.1	39
96	Improved Leakage Correction for Single-Echo Dynamic Susceptibility Contrast Perfusion MRI Estimates of Relative Cerebral Blood Volume in High-Grade Gliomas by Accounting for Bidirectional Contrast Agent Exchange. <i>American Journal of Neuroradiology</i> , 2016, 37, 1440-1446.	2.4	39
97	Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas Ligand pathway. <i>Journal of Translational Medicine</i> , 2011, 9, 192.	4.4	38
98	Autocrine Endothelin-3/Endothelin Receptor B Signaling Maintains Cellular and Molecular Properties of Glioblastoma Stem Cells. <i>Molecular Cancer Research</i> , 2011, 9, 1668-1685.	3.4	38
99	Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy. <i>Neuro-Oncology</i> , 2013, 15, 382-390.	1.2	38
100	Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide. <i>Molecular Cancer</i> , 2015, 14, 189.	19.2	38
101	Simultaneous p<sup>H</sup>-sensitive and oxygen-sensitive <sup>MRI</sup> of human gliomas at 3 <sup>T</sup> using multi-echo amine proton chemical exchange saturation transfer spin-echo gradient echo echo-planar imaging (<sup>CEST</sup>). <i>Magnetic Resonance in Medicine</i> , 2018, 80, 1962-1978.	3.0	38
102	WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2014, 2, 174.	5.2	37
103	MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab. <i>Journal of Neuro-Oncology</i> , 2015, 122, 497-505.	2.9	37
104	Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. <i>Neuro-Oncology</i> , 2012, 14, 1465-1472.	1.2	35
105	Pituitary adenylyl cyclase activating polypeptide inhibits gli1 gene expression and proliferation in primary medulloblastoma derived tumorsphere cultures. <i>BMC Cancer</i> , 2010, 10, 676.	2.6	34
106	Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 132, 351-358.	2.9	34
107	Subgroup and subtype-specific outcomes in adult medulloblastoma. <i>Acta Neuropathologica</i> , 2021, 142, 859-871.	7.7	34
108	Cellular immunity and immunotherapy of brain tumors. <i>Frontiers in Bioscience - Landmark</i> , 2004, 9, 3124.	3.0	33

#	ARTICLE	IF	CITATIONS
109	The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 11085-11096.	7.1	33
110	Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry. <i>Scientific Reports</i> , 2019, 9, 2846.	3.3	32
111	Robustness of gene expression profiling in glioma specimen samplings and derived cell lines. <i>Molecular Brain Research</i> , 2005, 136, 99-103.	2.3	31
112	Use of Language Mapping to Aid in Resection of Gliomas in Eloquent Brain Regions. <i>Neurosurgery Clinics of North America</i> , 2012, 23, 497-506.	1.7	31
113	Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 368-378.	1.2	31
114	Tumor-Suppressive miR148a Is Silenced by CpG Island Hypermethylation in IDH1-Mutant Gliomas. <i>Clinical Cancer Research</i> , 2014, 20, 5808-5822.	7.0	30
115	Cytokine responsiveness of CD8+ T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients. , 2014, 2, 10.		29
116	Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas. <i>Molecular Imaging and Biology</i> , 2015, 17, 434-442.	2.6	28
117	Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. <i>Neuro-Oncology</i> , 2019, 21, 1184-1196.	1.2	28
118	pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 142, 587-595.	2.9	28
119	Cellular and vaccine therapeutic approaches for gliomas. <i>Journal of Translational Medicine</i> , 2010, 8, 100.	4.4	26
120	Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 139, 651-659.	2.9	25
121	Immunotherapy for patients with malignant glioma: from theoretical principles to clinical applications. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 1481-1494.	2.8	24
122	Association between Tumor Acidity and Hypervascularity in Human Gliomas Using pH-Weighted Amine Chemical Exchange Saturation Transfer Echo-Planar Imaging and Dynamic Susceptibility Contrast Perfusion MRI at 3T. <i>American Journal of Neuroradiology</i> , 2019, 40, 979-986.	2.4	24
123	Human Astrocytes Exhibit Tumor Microenvironment-, Age-, and Sex-Related Transcriptomic Signatures. <i>Journal of Neuroscience</i> , 2022, 42, 1587-1603.	3.6	24
124	Lyophilized brain tumor specimens can be used for histologic, nucleic acid, and protein analyses after 1 year of room temperature storage. <i>Journal of Neuro-Oncology</i> , 2013, 113, 365-373.	2.9	23
125	Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study. <i>Scientific Reports</i> , 2020, 10, 11922.	3.3	23
126	Enhanced Sensitivity to IL-2 Signaling Regulates the Clinical Responsiveness of IL-12-Primed CD8+ T Cells in a Melanoma Model. <i>Journal of Immunology</i> , 2011, 186, 5068-5077.	0.8	22



#	ARTICLE	IF	CITATIONS
127	Hamartin expression and interaction with tuberin in tumor cell lines and primary cultures. <i>Journal of Neuroscience Research</i> , 2001, 63, 276-283.	2.9	21
128	Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. <i>Neuro-Oncology</i> , 2015, 17, vii32-vii40.	1.2	21
129	Current Status of Clinical Trials for Glioblastoma. <i>Reviews on Recent Clinical Trials</i> , 2006, 1, 265-281.	0.8	20
130	Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. <i>Neurosurgery</i> , 2019, 85, E607-E608.	1.1	20
131	Central Nervous System Tumor Immunity Generated by a Recombinant <i>Listeria monocytogenes</i> Vaccine Targeting Tyrosinase Related Protein-2 and Real-Time Imaging of Intracranial Tumor Burden. <i>Neurosurgery</i> , 2006, 58, 169-178.	1.1	17
132	Imaging biomarkers for antiangiogenic therapy in malignant gliomas. <i>CNS Oncology</i> , 2013, 2, 33-47.	3.0	17
133	Multiple calcifying pseudoneoplasms of the neuraxis (MCAPNON): Distinct entity, CAPNON variant, or old neurocysticercosis?. <i>Neuropathology</i> , 2017, 37, 233-240.	1.2	17
134	Essential Gene Pathways for Glioblastoma Stem Cells: Clinical Implications for Prevention of Tumor Recurrence. <i>Cancers</i> , 2011, 3, 1975-1995.	3.7	16
135	Dopamine Receptor Antagonists, Radiation, and Cholesterol Biosynthesis in Mouse Models of Glioblastoma. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1094-1104.	6.3	16
136	Improving B0 Correction for pH-Weighted Amine Proton Chemical Exchange Saturation Transfer (CEST) Imaging by Use of k-Means Clustering and Lorentzian Estimation. <i>Tomography</i> , 2018, 4, 123-137.	1.8	16
137	Tumor immunology, immunomics and targeted immunotherapy for central nervous system malignancies. <i>Neurological Research</i> , 2005, 27, 692-702.	1.3	15
138	Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden. <i>Neurosurgery</i> , 2020, 87, 931-938.	1.1	14
139	Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma. <i>Scientific Reports</i> , 2020, 10, 14819.	3.3	13
140	Voxelwise and Patientwise Correlation of <sup>18</sup> F-FDOPA PET, Relative Cerebral Blood Volume, and Apparent Diffusion Coefficient in Treatment-Naïve Diffuse Gliomas with Different Molecular Subtypes. <i>Journal of Nuclear Medicine</i> , 2021, 62, 319-325.	5.0	13
141	Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET. <i>Cancer Imaging</i> , 2021, 21, 27.	2.8	13
142	Nonlinear distortion correction of diffusion MR images improves quantitative DTI measurements in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2014, 116, 551-558.	2.9	12
143	Rationale and design of the 500-patient, 3-year, and prospective Vigilant Observation of Glioblastoma Treatment (VIGOR) registry. <i>CNS Oncology</i> , 2018, 7, CNS08.	3.0	12
144	Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas. <i>Brain Tumor Pathology</i> , 2018, 35, 1-9.	1.7	12

#	ARTICLE	IF	CITATIONS
145	Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors. <i>Neuro-Oncology</i> , 2022, 24, 1020-1028.	1.2	12
146	Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1565-1576.	4.1	11
147	Results From the CheckMate 143 Clinical Trial. <i>JAMA Oncology</i> , 2020, 6, 987.	7.1	11
148	High Order Diffusion Tensor Imaging in Human Glioblastoma. <i>Academic Radiology</i> , 2011, 18, 947-954.	2.5	10
149	Endogenous Vaults and Bioengineered Vault Nanoparticles for Treatment of Glioblastomas. <i>Neurosurgery Clinics of North America</i> , 2012, 23, 451-458.	1.7	10
150	Optical imaging for brain tissue characterization using relative fluorescence lifetime imaging. <i>Journal of Biomedical Optics</i> , 2013, 18, 060504.	2.6	10
151	Dendritic cell immunotherapy for brain tumors. <i>Journal of Neuro-Oncology</i> , 2015, 123, 425-432.	2.9	10
152	Effects of the DRD2/3 antagonist ONC201 and radiation in glioblastoma. <i>Radiotherapy and Oncology</i> , 2021, 161, 140-147.	0.6	10
153	GPIHBP1 expression in gliomas promotes utilization of lipoprotein-derived nutrients. <i>ELife</i> , 2019, 8, .	6.0	10
154	C-terminally truncated form of $\beta$ -crystallin is associated with IDH1 R132H mutation in anaplastic astrocytoma. <i>Journal of Neuro-Oncology</i> , 2014, 117, 53-65.	2.9	9
155	The Aging Neurosurgeon: When Is Enough, Enough? Attitudes Toward Ceasing Practice and Testing in Late Career. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1746-1752.	3.0	8
156	D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced <i>MIR148A</i> Promoter Methylation. <i>Molecular Cancer Research</i> , 2018, 16, 947-960.	3.4	8
157	SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation. <i>Journal of Neuro-Oncology</i> , 2019, 142, 423-434.	2.9	8
158	"Aerobic glycolytic imaging" of human gliomas using combined pH-, oxygen-, and perfusion-weighted magnetic resonance imaging. <i>NeuroImage: Clinical</i> , 2021, 32, 102882.	2.7	8
159	Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats. <i>Experimental and Molecular Pathology</i> , 2017, 103, 87-93.	2.1	7
160	Cell-Based Immunotherapy of Gliomas. <i>Progress in Neurological Surgery</i> , 2018, 32, 90-100.	1.3	7
161	Relative oxygen extraction fraction (rOEF) MR imaging reveals higher hypoxia in human epidermal growth factor receptor (EGFR) amplified compared with non-amplified gliomas. <i>Neuroradiology</i> , 2021, 63, 857-868.	2.2	7
162	Diversity in Neurosurgical Recruitment and Training in the United States: A Systematic Review. <i>World Neurosurgery</i> , 2022, 162, 111-117.e1.	1.3	7

#	ARTICLE	IF	CITATIONS
163	1-[(4-Nitrophenyl)sulfonyl]-4-phenylpiperazine treatment after brain irradiation preserves cognitive function in mice. <i>Neuro-Oncology</i> , 2020, 22, 1484-1494.	1.2	6
164	FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab017.	0.7	6
165	Targeting Stem Cells in Brain Tumors. <i>Technology in Cancer Research and Treatment</i> , 2006, 5, 251-260.	1.9	5
166	Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas. <i>Journal of Neuro-Oncology</i> , 2020, 149, 337-346.	2.9	5
167	Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden. <i>Annals of Nuclear Medicine</i> , 2021, 35, 1022-1029.	2.2	5
168	Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI. <i>Scientific Reports</i> , 2022, 12, 1078.	3.3	5
169	Title is missing!. <i>Journal of Neuro-Oncology</i> , 2003, 64, 21-30.	2.9	4
170	Correlation of commercially available quantitative MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival. <i>Neuro-Oncology Practice</i> , 2019, 6, 194-202.	1.6	4
171	Brain Tumor Vaccines. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 225-234.	1.7	4
172	Maintenance of Certification: Perceptions and Attitudes of Neurosurgeons. <i>Neurosurgery</i> , 2018, 83, 835-842.	1.1	3
173	Developing a Professionalism and Harassment Policy for Organized Neurosurgery. <i>Neurosurgery</i> , 2021, 88, 1038-1039.	1.1	3
174	Recognized focused practice: Does sub-specialty designation offer value to the neurosurgeon?. <i>PLoS ONE</i> , 2017, 12, e0189105.	2.5	3
175	Preferential tumor localization in relation to 18F-FDOPA uptake for lower-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2021, 152, 573-582.	2.9	2
176	Editorial. Sexual harassment in neurosurgery: #UsToo. <i>Journal of Neurosurgery</i> , 2020, , 1-3.	1.6	2
177	Continuous improvement in patient safety and quality in neurological surgery: the American Board of Neurological Surgery in the past, present, and future. <i>Journal of Neurosurgery</i> , 2020, , 1-7.	1.6	2
178	Diagnostic and Prognostic Value of pH- and Oxygen-Sensitive Magnetic Resonance Imaging in Glioma: A Retrospective Study. <i>Cancers</i> , 2022, 14, 2520.	3.7	2
179	Introduction: brain tumor immunotherapy. <i>Journal of Neuro-Oncology</i> , 2015, 123, 321-322.	2.9	1
180	Glioblastoma: Molecular Mechanisms and Clinical Trials. <i>Neurosurgery Clinics of North America</i> , 2021, 32, xiii.	1.7	1

#	ARTICLE	IF	CITATIONS
181	Ascending dose trials of the safety and tolerability of Toca 511, a retroviral replicating vector encoding cytosine deaminase, in patients with recurrent high-grade glioma.. Journal of Clinical Oncology, 2012, 30, 2101-2101.	1.6	1
182	Developing a professionalism and harassment policy for organized neurosurgery. Journal of Neurosurgery, 2021, 134, 1-2.	1.6	1
183	Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable Disease. Frontiers in Oncology, 2022, 12, 849993.	2.8	1
184	Editorsâ€™ Message to the Readership. Journal of Neuro-Oncology, 2008, 86, 1-1.	2.9	0
185	BI-10 * pH-WEIGHTED MRI IN HUMAN GLIOMAS. Neuro-Oncology, 2014, 16, v25-v25.	1.2	0
186	Radial Mobility and Cytotoxic Function of Retroviral Replicating Vector Transduced, Non-adherent Alloresponsive T Lymphocytes. Journal of Visualized Experiments, 2015, , .	0.3	0
187	IMCT-11NEXT GENERATION T CELL RECEPTOR SEQUENCING CAN IDENTIFY, QUANTIFY, AND TRACK TUMOR-SPECIFIC T CELL POPULATIONS BEFORE AND AFTER DENDRITIC CELL VACCINATION IN GLIOBLASTOMA MULTIFORME PATIENTS. Neuro-Oncology, 2015, 17, v109.4-v110.	1.2	0
188	TMIC-04THERAPEUTIC ANTI-GLIOMA IMMUNITY IS DEPENDENT ON VACCINATION-INDUCED T CELL RESPONSES AND INHIBITION OF iAPC FUNCTION IN THE TUMOR MICROENVIRONMENT. Neuro-Oncology, 2015, 17, v214.8-v215.	1.2	0
189	Risk factors for platelet transfusion in glioblastoma surgery. Journal of Clinical Neuroscience, 2018, 50, 93-97.	1.5	0
190	Next-Generation Sequencing and Personalized Medicine for Brain Cancer. Current Surgery Reports, 2018, 6, 1.	0.9	0
191	Overview of Dendritic Cell Vaccines for Brain Tumors. , 2018, , 681-692.		0
192	Benefit of MGMT methylation in glioblastoma in relation to hTERT promoter mutation.. Journal of Clinical Oncology, 2016, 34, 2006-2006.	1.6	0
193	Improving care coordination for brain tumor patients through value-based care redesign of a virtual integrated practice unit.. Journal of Clinical Oncology, 2017, 35, 110-110.	1.6	0